Rats and guinea pigs developed pronounced erythrocytosis at one to four months after unilateral intrarenal (ir) injection of nickel subsulfide (Ni3S2). For example, at two months after ir administration of Ni3S2 (5 mg) to rats, blood hematocrit values averaged 70 i 3 percent (p < 0.001 vs. 48 + 2 in controls); at two months after ir administration of Ni3S2 (20 mg) to guinea pigs, blood hematocrit values averaged 67 6 percent (p < 0.001 vs. 49 i 1 percent in controls). Hamsters and gerbils did not develop erythrocytosis after ir injection of Ni3S2 (5 mg/animal). Administration of Ni3S2 to rats by intrasplenic injection did not increase blood hematocrit; splenectomy did not prevent erythrocytosis in rats that received ir injection of Ni3S2. Erythrocytosis in rats was completely blocked by excision of the Ni3S2-injected kidney but was unaffected by excision of the non-injected kidney. Partial inhibition of Ni3S2-induced erythrocytosis in rats occurred after simultaneous ir injection of Mn, Cu, or Al dusts, benzo(a)pyrene, or subcutaneous (sc) infusion of sodium diethyldithiocarbamate. Erythrocytosis induced by ir injection of Ni3S2 was augmented by ir injection of Cr dust or intramuscular (im) administration of iron-dextran. Erythrocytosis occurred in rats after ir implantation of Ni3S2 within semi-permeable cellulose tubules, indicating that phagocytosis of Ni3S2 particles is unnecessary for erythropoietic stimulation. Erythropoietin (Ep) activity in rat serum increased sixfold at two weeks after ir injection of Ni3S2 (p < 0.001 vs. controls), but Ep activity in pooled extracts of Ni3S2-treated rat kidneys did not increase significantly. This study identifies several factors that influence erythropoietic stimulation by Ni3S2, and furnishes salient information concerning the pathogenesis of Ni3S2-induced erythrocytosis.
INTRODUCTION
In 1973, Jasmin [ 11 noted that rats develop polycythemia within one month after an intrarenal (ir) injection of nickel subsulfide (Ni3S2). Subsequent studies confirmed that blood hematocrit, hemoglobin concentration, and erythrocyte count are significantly increased from one week to approximately six months following ir injection of 5 or 10 mg of Ni3S2 [2] [3] [4] . Blood hematocrit values are greatest at six to 12 weeks; highest reticulocyte counts and maximum incorporation of 59Fe into erythrocytes occur at two to four weeks . Pronounced erythroid hyperplasia is present in bone marrow of rats from two weeks to five months after ir injection of Ni3S2 [3, 7, 9, 10] . In rats that receive ir injection of 5 or 10 mg of Ni3S2, the circulating erythrocyte mass undergoes 2 to 2.5-fold enlargement; the plasma volume is slightly diminished, and the concentration of 2,3-diphosphoglycerate in erythrocytes remains normal [2, 3, 10] . When 51Cr-tagged erythrocytes from Ni3S2-treated rats are transfused into normal recipients, the circulating half-life of the labelled cells is prolonged, consistent with an increased proportion of juvenile erythrocytes [7] . Ni3S2-induced erythrocytosis is unaccompanied by leukocytosis or thrombocythemia [3, 10] . Erythrocytosis does not occur in rats after administration of Ni3S2 by intramuscular (im), intravenous (iv), or intrahepatic injection, or after sustained intraperitoneal (ip) infusion of NiCl2 [3, 4, 7, 8, 11] .
Induction of erythrocytosis by ir administration seems to be peculiar to nickel compounds, inasmuch as ir injections of Au, Cd, Co, CoS, Cr, Cu, Fe, Mn, and Pb dusts do not stimulate erythrocytosis in rats [12, 13] . The erythropoietic effects of 17 nickel compounds have been tested by ir administration to rats [13] . In order of decreasing potency, the following compounds cause significant increases of blood hematocrit: Ni3S2 > NiO > NiSe > NiS2 > NiS > Ni3Se2 > Ni4FeS4 > Ni dust > NiAsS [13] . Equivalent doses of the following compounds do not affect blood hematocrit under the same conditions: amorphous NiS, NiTe, NiAs, Nil,As5, Ni5As2, NiSb, NiFe, and NiTiO3 [13] . Stimulation of erythropoiesis in rats by ir injection of nickel compounds does not correlate with phagocytosis of the compounds by rat peritoneal macrophages in vitro [13, 14] , or dissolution of the compounds during incubation in rat serum or renal cytosol [13, 15] . Ni3S2-induced erythrocytosis in rats is inhibited by simultaneous ir injection of Mn dust [16] . Until the present study, Ni3S2 was known to induce erythrocytosis only in rats; ir injection of Ni3S2 does not cause erythrocytosis in mice (BALBc strain) or squirrels [7] .
Several reports have described the pathological lesions that develop in rats after ir injection of Ni3S2 [3, 7, 9, 17, 18] . Inflammation and fibrosis occur along the needle tract in the injected kidney [3, 7] ; Ni3S2-particles are phagocytized by mononuclear cells and glomerular mesangial cells [9] ; renal glomeruli become enlarged [9] ; mesangial cells become hyperplastic [9] ; and crystalline mitochondrial inclusions develop in renal tubular cells [17, 18] . Carcinomas and sarcomas frequently become evident in the injected kidneys of rats at eight to 20 months after ir injection of Ni3S2 [4, 12, 19] . Other pathological findings include splenomegaly, cardiomegaly, sialyl hyperplasia, and arteriosclerosis [9] .
The following evidence suggests that Ni3S2-induced erythrocytosis is mediated by increased renal production of erythropoietin (Ep): (a) Ep activity is increased in rat serum at two to eight weeks after ir injection of Ni3S2 [6, 10, 11] ; (b) erythrogenin activity is increased in the light mitochondrial fraction from kidneys of Ni3S2-treated rats [10] ; (c) Ni3S2-induced erythrocytosis is reversed by resection of the injected kidney [10, 11] ; (d) Ni3S2-induced erythrocytosis is suppressed by prolonged exposure to hyperoxia [10] ; and (e) Ni3S2-induced erythrocytosis is prevented by ip infusion of anti-Ep antiserum [10] .
The present paper describes ten experiments on Ni3S2-induced erythrocytosis that furnish salient information concerning species-specificity, route of administration, effects of nephrectomy and splenectomy, inhibition by chelating agents; antagonism by metal dusts, role of phagocytosis, effect of iron-dextran treatment, response to simultaneous ir injection of benzo(a)pyrene, and erythropoietin activity in renal cytosol.
MATERIALS AND METHODS

Test Materials
Nickel subsulfide (aNi3S2, median particle diameter < 2 /im) was donated by Stuart Warner, Ph.D., INCO Ltd., Toronto, Canada. The chemical and physical properties of the Ni3S2 sample were described previously [19, 20] . Mn, Cu, Cr, and Al dusts (median particle diameters < 5 lim) were obtained from Alfa Inorganic Products Division, Ventron Corp., Danvers, MA. Purity of the metal dusts was > 99.9 percent, based upon the producer's specifications. Benzo(a)pyrene (Mann Research Laboratories, Inc., New York, NY) yielded a single fluorescent spot after thin-layer chromatography, as previously described [21] . Iron-dextran solution ["Imferon," Fe(OH)3-dextran complex (50 mg Fe/ml), dissolved in NaCl solution (0.14 mol/liter)] was obtained from Richardson Merrill, Inc., Cincinnati, OH. d-Penicillamine (d-3-mercaptovaline hydrochloride) was obtained from Aldrich Chemical Co., Milwaukee, WI. Sodium diethyldithiocarbamate trihydrate (Sigma Chemical Co., St. Louis, MO) was recrystallized, as previously described [22] . Lyophilized sheep erythropoietin ("Stage 3 Preparation," Connaught Laboratories, Ltd., Swiftwater, PA) was the standard for erythropoietin bioassays.
Experimental Animals
The animals included 596 male rats (Fischer-344 strain, mean body weight = 230 g, SD + 44 g. Charles River Breeding Laboratories, Inc., Wilmington, MA); 120 virgin female mice (CF-I strain, mean body weight = 27 g, SD 2 g, Charles River Breeding Laboratories, Inc.); 19 male guinea pigs (Hartley strain, mean body weight = 534 g, SD + 18 g, Buckberg Laboratory Animals, Inc., Tomkins Cove, NY); 22 male hamsters (Syrian golden strain, mean body weight = 117 g, SD + 13 g. Charles River Breeding Laboratories, Inc.); and 19 male Mongolian gerbils (mean body weight = 90 g, SD 13 g, bred in the University of Connecticut Vivarium, Farmington, CT). The animals were fed the appropriate Purina laboratory animal chows and water ad libitum. Gerbils received parenteral iron supplementation (Imferon, 2.5 mg Fe/gerbil, im) at biweekly intervals. Rats and guinea pigs were housed in stainless steel cages; mice, hamsters, and gerbils were housed in polypropylene cages with wood chip bedding.
Treatments
Anesthesia with diethylether was used for animal surgery. The kidney was exposed by a subcostal lumbar incision. For ir injection, the test substance [suspended in 0.1 to 0.25 ml of NaCl solution (0.14 mol/liter) or glycerol (50 percent solution in distilled water)] was injected into the kidney by a tuberculin syringe with No. 25 gauge needle. For nephrectomy, the ureter and renal vessels were ligated with silk sutures, and the kidney was excised with fine scissors. After ir injection or nephrectomy, the lumbar muscles were sutured with silk, and the skin incision was closed with surgical clips. For intrasplenic injection or splenectomy, similar procedures were used; the abdominal cavity was opened by a midline incision. In one experiment, osmotically driven pumps ("Alzet minipumps," model 2001, infusion rate = 1 MLl/hr, Alza Corp., Palo Alto, CA) were employed for sc infusion of chelating agents, as previously described [23] . The pumps were replaced at seven-day intervals during the 35 days of treatment. In another experiment, semipermeable tubules ("Diaflo H1OX50 Fibers," nominal molecular exclusion limit = 50,000 daltons, 0.5 mm internal diameter, 6 mm length, Amicon Corp., Lexington, MA) were implanted in rat kidneys. Each tubule was filled with Ni3S2 by the following procedure: (a) the empty tubule was weighed, (b) a tiny wad of cotton was inserted in one end, (c) the partially plugged end of the tubule was connected to suction via a blunt needle, (d) Ni3S2 powder was aspirated into the tubule from a weighing boat, (e) the cotton wad was removed, (f) the tubule was reweighed to determine the Ni3S2 content, and (g) both ends were sealed by application of forceps that had been heated in a flame. A No. 18 gauge needle was inserted into the rat kidney to a depth of 8 mm, with care to avoid the renal calyx. The needle was withdrawn, and the tubule was gently pushed into the renal parenchyma along the needle track.
Hematological Tests
Blood samples (-50 1l) were obtained from tails of rats and gerbils, from toepads of guinea pigs, and from retro-orbital venous plexuses of mice and hamsters. The blood samples were collected in heparinized capillary tubes; microhematocrit determinations were performed by the method of Strumia et al. [24] . Bioassays of erythropoietin (Ep) activity were performed upon serum and renal extracts from groups of 12 to 28 rats. The rats were exsanguinated by cardiocentesis, and 2 ml samples of serum from each rat were pooled. Each kidney was perfused in situ with 12 ml of cold phosphate-buffered NaCl solution (Na2HPO4-KH2PO4 buffer, pH 7.0, 10 mmol/liter; NaCl, 0.14 mol/liter, 4°C). The kidneys were homogenized in phosphate-buffered NaCl solution and centrifuged at 2300 xg for 30 minutes, as described by Fried et al. [25] . Each ml of renal extract corresponded to 0.33 g of kidney (wet weight). Each sample of pooled rat serum and pooled renal extract was apportioned into 12 tubes; the tubes were stored at -20°C; one tube was thawed immediately prior to each dosing in the Ep bioassay. Ep activity was measured in groups of four to six post-hypoxic polycythemic mice, as previously described [6] . Each mouse received 12 injections sc of 0.5 ml of pooled serum, renal extract, or Ep standard solution at six-hour intervals for three days (total dose = 6 ml per mouse). Ep activities of rat serum and renal extract were read from a six-point logit calibration plot of erythrocyte "9Fe-uptake in mice that received injections of sheep Ep standard solutions (8 to 500IU/liter). The Ep detection limit was 12IU/liter, defined as the concentration of Ep that yielded a response differing by its standard deviation multiplied by Student's t value for p = 0.05 from the response for "zero" dose (NaCl vehicle solution) [6] . Null hypothesis for differences between observations in treated and control groups were tested by Student's t test [26] .
RESULTS
Species Susceptibility Experiment
Blood hematocrit was measured in groups of rats, hamsters, gerbils, and guinea pigs at one to four months after unilateral ir injection of Ni3S2 at dosages specified in Table 1 . Control groups received ir injection of NaCl vehicle. No significant changes of blood hematocrit were observed in Ni3S2-treated hamsters and gerbils; significant increases of blood hematocrit were found in Ni3S2-treated rats and guinea pigs throughout the period of study. For example, at two months after ir injection of Ni3S2, the average increase of blood hematocrit in rats was 46 percent and that in guinea pigs was 38 percent, (p < 0.001 vs. corresponding values in controls). 
Injection Route Experiment
Groups of rats were given intrasplenic or intrarenal injections of NaCl vehicle or Ni3S2 (10 mg/rat). As indicated in Table 2 , blood hematocrit values were consistently increased at one to four months after ir injection of Ni3S2 (p < 0.001), whereas blood hematocrit values did not change significantly after intrasplenic administration of Ni3S2.
Splenectomy Experiment
Splenectomy or sham splenectomy (with exposure and palpation of the spleen) were performed in groups of rats at five days before or after ir injection of NaCl vehicle or Ni3S2 (5 mg/rat) ( Table 3) . Splenectomy had no effect upon blood hematocrit values in vehicle-treated controls. Splenectomy did not suppress the development of erythrocytosis in Ni3S2-treated rats.
Nephrectomy Experiment
Groups of rats were subjected to unilateral nephrectomy on the fourth day after injection of NaCl vehicle or Ni3S2 (5 mg/rat) into the right kidney (Table 4) . Exci- aNaCi vehicle (0.14 mol/liter, 0.2 ml/rat) was injected into the spleen.
bNaCl vehicle (0.14 mol/liter, 0.1 ml/rat) was injected into the right kidney.
cp < 0.001 vs. corresponding value in vehicle controls. bInjection of NaCl vehicle (0.14 mol/liter, 0.2 ml/rat) or Ni3S2 into the right kidney.
cp < 0.001 vs. corresponding value in vehicle controls. dp < 0.001 vs. corresponding value in Ni3S2-treated controls. 
Metal Interactions Experiment
Four metal dusts (Mn, Cr, Cu, and Al) were administered to groups of rats by ir injection (8 mg/rat), alone, or in combination with Ni3S2 (2.5 mg/rat). In the absence of Ni3S2, the four metal dusts had no significant effects upon blood hematocrit values (Table 6 ). Consistent with previous findings [16] , induction of erythrocytosis at one and two months after ir injection of Ni3S2 was partially suppressed by admixture of Mn dust. Similar, but less marked, suppression of Ni3S2-induced erythrocytosis was also noted at one month after ir injection of Cu dust and Ni3S2, and at four months after ir injection of Al dust and Ni3S2. Enhancement of erythrocytosis was observed at two to four months after ir injection of Cr dust and Ni3S2, compared to that produced by Ni3S2, alone.
Semi-Permeable Tubule Experiment
Blood hematocrit values of rats were increased at one to four months after ir implanation of sealed cellulose tubules that contained 10 mg of Ni3S2 (Table 7 ). This observation indicates that phagocytosis of Ni3S2 particles is not essential for Ni3S2-induced erythrocytosis. Blood hematocrit values were also increased in rats at one to four months after ir implantation of Ni3S2-containing tubules that had been punctured 20 times with a needle. However, hematocrit values in these rats were not significantly higher than in rats that received ir implants of sealed Ni3S2-containing tubules.
Effect of Iron-Dextran Treatment
To ascertain whether augmentation of body iron stores might influence Ni3S2-induced erythrocytosis, iron-dextran complex ("Imferon") was administered to rats (Table 9 ). When a mixture of benzo(a)pyrene and Ni3S2 was administered ir to rats, benzo(a)pyrene partially inhibited Ni3S2-induced erythrocytosis throughout the period from one to four months after the injection. Suppression of Ni3S2-induced erythrocytosis was not observed when benzo(a)pyrene was injected in the left kidney and Ni3S2 was injected in the right kidney. Erythropoietin Bioassays To determine whether increased Ep activity in serum of Ni3S2-treated rats is associated with increased Ep activity in kidney, Ep bioassays were performed upon pooled serums and renal extracts from rats killed at two weeks after ir injection of Ni3S2 or NaCl vehicle solution (Table 10 , Experiment A). Consistent with previous findings [6, 10, 11] , Ep activity was increased sixfold in serum of Ni3S2-treated rats (p < 0.001 vs. controls). Ep activity in pooled extracts of right (injected) kidneys aAll rats received Imferon (iron-dextran, 5 mg Fe/rat, im) one week before and 1, 3, 5, 7, 9, and 11 weeks after the ir injection. bGlycerol vehicle (50 percent, v/v; 0.2 ml/rat) was injected into the right kidney. cBenzo(a)pyrene (2 mg/rat) and Ni3S2 (2 mg/rat) were administered as a single injection in 0.2 ml of glycerol vehicle into the right kidney. dBenzo(a)pyrene (2 mg/rat, in 0.2 ml of glycerol vehicle) was injected into the left kidney, and Ni3S2 (2 mg/rat, in 0.2 ml of glycerol vehicle) was injected into the right kidney. aRats were killed two weeks after injection of NaCl vehicle (0.14 mol/liter, 0.2 ml/rat) or Ni3S2 in the right kidney. bPooled serums or renal extracts were administered to post-hypoxic polycythemic mice as 12 sc injections (0.5 ml/mouse at six-hour intervals during three days; total dose = 6 ml/mouse).
C"9Fe-labelled ferrous citrate solution (2 ACi 59Fe/mouse) was injected iv at eight hours after the last sc injection of serum or renal extract; "9Fe-uptake into circulating erythrocytes was measured at 24 hours after the ferrous citrate injection. dp < 0.01 vs. corresponding value for control rats. *p < 0.001 vs. corresponding value for pooled serum from control rats. [7] show that these species are refractory to Ni3S2-induction of erythrocytosis. In hamsters, blood hematocrit at two months after ir injection of Ni3S2 averaged 12 percent greater than in controls; this slight increase was not statistically significant. In future studies, we shall determine whether significant erythrocytosis develops in hamsters after ir injection of larger doses of Ni3S2.
Role of the Spleen
The possible involvement of the spleen in Ni3S2-stimulation of erythropoiesis was investigated, since splenomegaly and splenic erythroid hyperplasia occur in rats after ir injection of Ni3S2 [9] , and since the spleen has been proposed as an extrarenal source of erythropoietin [27] [28] [29] . In the present study, intrasplenic injection of Ni3S2 did not affect blood hematocrit in rats, and splenectomy did not significantly influence the erythrocytosis that occurs after ir injection of Ni3S2. Therefore, the spleen does not play an essential role in the pathogenesis of Ni3S2-induced erythrocytosis. The lack of erythropoietic response to intrasplenic injection of Ni3S2 is consistent with the previously reported lack of erythropoietic response to intrahepatic injection of Ni3S2 in rats following partial hepatectomy [7] . To date, ir injection is the only route of Ni3S2 administration that has been found to evoke erythrocytosis in rats.
Nephrectomy
McCully et al. [9] speculated that glomerular mesangial cells may be responsible for Ep production in Ni3S2-treated rats, based upon the occurrence of glomerulomegaly and hyperplasia of mesangial cells in both kidneys of rats at one to 18 weeks after unilateral ir injection of Ni3S2. The present nephrectomy experiment shows that excision of the non-injected (left) kidney does not diminish the erythropoietic response, whereas excision of the injected (right) kidney completely prevents the response. The possible involvement of the contralateral kidney in the pathogenesis of Ni3S2-induced erythrocytosis has not hitherto been investigated; consistent with previous findings [10, 11] , presence of the injected kidney appears to be essential for Ni3S2-induction of erythrocytosis. Since mesangial cell hyperplasia occurs with equal intensity in both kidneys [9] , the results of the nephrectomy experiment militate against the hypothesis that hyperplastic mesangial cells are responsible for Ep production in Ni3S2-treated rats.
Effects of Chelators
Studies in rats indicate that diethyldithiocarbamate is superior to d-penicillamine for treatment of nickel carbonyl poisoning [22] , but less effective than d-penicillamine as an antidote for nickel chloride poisoning [39] . Ni[II]-bis-diethyldithiocarbamate is lipophilic and Ni[II]-penicillamine is hydrophilic; these differences in chemical properties result in disparate effects of diethyldithiocarbamate and penicillamine on the tissue distribution of 63Ni[II] [31] . The present study shows that ip infusion of diethyldithiocarbamate partially suppresses the erythropoietic response to ir injection of Ni3S2 in rats, whereas d-penicillamine has no inhibitory effect. The inhibitory action of diethyldithiocarbamate on Ni3S2-induced erythrocytosis may be unrelated to its chelating affinity for nickel, since diethyldithiocarbamate also protects rats against the toxicity of carbon tetrachloride [32] and dimethylnitrosamine [33] .
Effects of Metal Dusts
At one month after ir injection of Mn dust in combination with Ni3S2, Mn dust completely blocks Ni3S2-induced erythrocytosis. The inhibitory effect of Mn dust on erythropoietic stimulation by Ni3S2 is less marked at two months; the inhibition is no longer significant at three months after the ir injection. Manganese has also been reported to antagonize the actions of nickel in other experimental systems; (a) Mn dust suppresses the carcinogenicity of Ni3S2 following im and ir administration to rats [19, 20] [39, 40] . Manganese influences the intracellular distribution of nickel, since ultrafiltrable 63Ni concentration in muscle cytosol is diminished in rats that receive im injection of Mn dust and 63Ni3S2, in comparison to rats that receive im injection of 63Ni3S2, alone [20] . The molecular mechanism of manganese-nickel antagonism has not been identified.
The present study indicates that Cu and Al dusts suppress Ni3S2-induced erythrocytosis in rats at one month and four months, respectively, after ir injection. The inhibitory effect of Cu dust is particularly interesting, since Cu[II] displaces Ni[II] from its binding site near the N-terminus of human albumin [41] . Enhanced erythrocytosis was noted in the present study at two to four months after combined ir injection of Cr dust and Ni3S2, compared to that produced by Ni3S2, alone. This observation is consistent with a recent report that Cr [III] potentiates the toxic effects of Ni [II] in cell cultures of murine fibroblasts [42] . Semi-Permeable Tubules Stimulation of erythropoiesis was observed in the present study in rats that received ir implants of Ni3S2 within semipermeable tubules (nominal molecular exclusion limit = 50,000 daltons). The erythrocytosis was not significantly augmented when Ni3S2-containing tubules were punctured several times with a needle prior to ir implantation. In a pilot study that was reported previously [7] , erythrocytosis did not develop in five rats that received ir implants of Ni3S2 within sealed tubules with larger pores (nominal molecular exclusion limit = 150,000 daltons). We attribute the discrepancy between the results of the pilot study and the present experiment to (a) improved implantation technique, with less peritubular hemorrhage, and (b) less obstruction of the smaller pores by fibrin. Ni3S2 gradually dissolves within the lumen of the cellulose tubules; Ni[II]-complexes with amino acids, peptides, and low molecular weight proteins slowly diffuse through the pores into the renal parenchyma [7, 43] . The present experiment demonstrates that phagocytosis of Ni3S2 particles within the renal parenchyma is not essential for the induction of erythrocytosis. Effects of Imferon and Benzo(a)pyrene Supplementation of body iron stores by biweekly im administration of irondextran ("Imferon") augmented erythrocytosis in rats after ir injection of Ni3S2. This observation suggests that dietary intake of iron from Purina laboratory rat chow is insufficient to sustain the maximal rate of erythrocyte production in Ni3S2-treated rats. Reports of carcinogenic synergism between benzo(a)pyrene and nickel compounds [21, 44, 45] prompted us to administer benzo(a)pyrene and Ni3S2 to rats, singly and in combination, by ir injection. Instead of enhancing Ni3S2-induced erythrocytosis, benzo(a)pyrene partially inhibited the erythropoietic response. This finding provides a novel experimental system to investigate the metabolic interactions of benzo(a)pyrene and nickel compounds. Erythropoietin Bioassays Renal extracts, prepared by the method of Fried et al. [25] , and pooled serums from Ni3S2-treated and control rats were assayed for Ep activity in post-hypoxic polycythemic mice. The bioassays demonstrated increased Ep activity in serum, but not in renal extracts of Ni3S2-treated rats. This finding is consistent with the concept that a renal erythropoietic factor ("erythrogenin") is produced by the kidney and acts in concert with a serum component to produce the active Ep molecule [46, 47] . Meagher [10] detected increased erythrogenin activity in the light mitochondrial fraction from injected kidneys of Ni3S2-treated rats. Attempts to confirm Meagher's observation and to investigate the mechanism whereby Ni3S2 stimulates renal erythrogenin activity are under way in our laboratory.
